Doximity (NASDAQ:DOCS – Free Report) Morgan Stanley raised its price target from $25.00 to $26.00 in a research note published Friday, Benzinga reports. The brokerage currently has an “underweight” rating on the stock.
A number of other equities analysts also recently issued reports on DOCS. Evercore ISI raised their price target on shares of Doximity from $28.00 to $29.00 and gave the company an in-line rating in a research note on Friday, May 17th. Needham & Company LLC upgraded Doximity from a hold rating to a buy rating and set a $38.00 price target on the stock in a research note on Friday. Wells Fargo & Company downgraded Doximity from an equal-weight rating to an underweight rating and decreased their price target for the company from $27.00 to $19.00 in a research note on Thursday, July 18th. William Blair reiterated an outperform rating on shares of Doximity in a research note on Friday, May 17th. Finally, JPMorgan Chase & Co. raised Doximity from an underweight rating to a neutral rating and set a $25.00 price target for the company in a research report on Thursday, April 25. Two analysts have rated the stock with a sell rating, eight have given a hold rating, and three have given a buy rating. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $29.64.
Check out our latest stock analysis on Doximity
Doximity price development
NASDAQ:DOCS opened at $35.60 on Friday. The company’s 50-day moving average is $28.00 and its 200-day moving average is $27.31. Doximity has a 1-year low of $19.71 and a 1-year high of $35.79. The company has a market cap of $6.60 billion, a price-to-earnings ratio of 49.44, a PEG ratio of 5.12 and a beta of 1.22.
Doximity (NASDAQ:DOCS – Free Report) last released its quarterly earnings results on Thursday, August 8. The company reported earnings per share of $0.22 for the quarter, beating the consensus estimate of $0.16 by $0.06. Doximity had a return on equity of 17.44% and a net margin of 31.04%. The company had revenue of $126.68 million during the quarter, compared to analyst estimates of $119.88 million. Overall, equities analysts expect that Doximity will post earnings per share of $0.74 for the current fiscal year.
Insider transactions at Doximity
In related news, CFO Anna Bryson sold 30,000 shares of the company’s stock on Wednesday, June 12. The shares were sold at an average price of $30.00, for a total transaction of $900,000.00. Following the completion of the transaction, the CFO now directly owns 288,685 shares of the company’s stock, valued at $8,660,550. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC’s website. In other news, Director Watkin Phoebe L. Yang sold 1,011 shares of the company’s stock on Monday, August 5. The shares were sold at an average price of $25.54, for a total transaction of $25,820.94. Following the completion of the sale, the director now directly owns 11,258 shares of the company’s stock, valued at approximately $287,529.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC’s website. Also, CFO Anna Bryson sold 30,000 shares of the company’s stock on Wednesday, June 12. The shares were sold at an average price of $30.00, for a total value of $900,000.00. Following the transaction, the chief financial officer now owns 288,685 shares of the company’s stock, valued at approximately $8,660,550. The disclosure of this sale can be found here. In the last ninety days, insiders sold 81,951 shares of the company’s stock, valued at $2,574,843. 39.40% of the shares are currently owned by company insiders.
Institutional investors comment on Doximity
Institutional investors and hedge funds have recently added to or reduced their holdings in the company. Lmcg Investments LLC increased its holdings in shares of Doximity by 13.6% in the 2nd quarter. Lmcg Investments LLC now owns 144,827 shares of the company’s stock valued at $4,051,000 after acquiring an additional 17,283 shares during the period. Renaissance Technologies LLC increased its holdings in Doximity by 23.1% in the 2nd quarter. Renaissance Technologies LLC now owns 1,603,202 shares of the company’s stock valued at $44,842,000 after acquiring an additional 301,100 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Doximity by 28.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,267,067 shares of the company’s stock valued at $35,439,000 after buying an additional 281,239 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in Doximity by 16.5% in the second quarter. Envestnet Asset Management Inc. now owns 148,584 shares of the company’s stock valued at $4,156,000 after buying an additional 21,005 shares during the same period. Finally, Oppenheimer Asset Management Inc. increased its stake in Doximity by 48.2% in the second quarter. Oppenheimer Asset Management Inc. now owns 22,705 shares of the company’s stock valued at $635,000 after buying an additional 7,385 shares in the last quarter. Hedge funds and other institutional investors own 87.19% of the company’s stock.
Doximity company profile
(Get free report)
Doximity, Inc. operates a cloud-based digital platform for healthcare professionals in the United States. The company’s platform provides its members with tools for healthcare professionals to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date on the latest medical news and research, and manage their careers.
More information
Get daily news and reviews for Doximity – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Doximity and related companies with MarketBeat.com’s FREE daily email newsletter.
